R
Robert M. Berman
Researcher at Bristol-Myers Squibb
Publications - 64
Citations - 3103
Robert M. Berman is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Aripiprazole & Placebo. The author has an hindex of 25, co-authored 64 publications receiving 2837 citations.
Papers
More filters
Journal ArticleDOI
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder : A multicenter, randomized, double-blind, placebo-controlled study
Robert M. Berman,Ronald N. Marcus,Rene Swanink,Robert D. McQuade,William H. Carson,Patricia K. Corey-Lisle,Arif Ullah Khan +6 more
TL;DR: In patients with MDD who showed an incomplete response to ADT, adjunctive aripiprazole was efficacious and well tolerated.
Journal ArticleDOI
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Ronald N. Marcus,Robert D. McQuade,William H. Carson,Delphine Hennicken,Maurizio Fava,Jeffrey S. Simon,Madhukar H. Trivedi,Michael E. Thase,Robert M. Berman +8 more
TL;DR: Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT.
Journal ArticleDOI
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Vladimir Coric,Christopher H. van Dyck,Stephen Salloway,Niels Andreasen,Mark Brody,Ralph W. Richter,Hilkka Soininen,Stephen G. Thein,Thomas Shiovitz,Gary Pilcher,Susan Colby,Linda Rollin,Randy C. Dockens,Chahin Pachai,Erik Portelius,Ulf Andreasson,Kaj Blennow,Holly Soares,Charles F. Albright,Howard Feldman,Robert M. Berman +20 more
TL;DR: This study establishes an acceptable safety and tolerability dose range for future avagacestat studies in AD and provides preliminary support for -secretase target engagement in patients with mild to moderate Alzheimer disease.
Journal ArticleDOI
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Robert M. Berman,Maurizio Fava,Michael E. Thase,Madhukar H. Trivedi,Rene Swanink,Robert D. McQuade,William H. Carson,David E. Adson,L. P. Taylor,James Hazel,Ronald N. Marcus +10 more
TL;DR: This is the third consecutive clinical trial to demonstrate that aripiprazole augmentation to antidepressants is an efficacious and well-tolerated treatment for patients with MDD who do not respond adequately to standard antidepressant monotherapy.
Journal ArticleDOI
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Vladimir Coric,Stephen Salloway,Christopher H. van Dyck,Bruno Dubois,Niels Andreasen,Mark Brody,Craig Curtis,Hilkka Soininen,Stephen G. Thein,Thomas Shiovitz,Gary Pilcher,Steven H. Ferris,Susan Colby,Wendy Kerselaers,Randy C. Dockens,Holly Soares,Stephen Kaplita,Feng Luo,Chahin Pachai,Luc Bracoud,Mark A. Mintun,Joshua D. Grill,Ken Marek,John Seibyl,Jesse M. Cedarbaum,Charles F. Albright,Howard Feldman,Robert M. Berman +27 more
TL;DR: Avagacestat did not demonstrate efficacy and was associated with adverse dose-limiting effects in this PDAD population, which had higher rates of clinical progression to dementia and greater brain atrophy compared with CSF biomarker-negative participants.